Business Wire

SEOUL-VIOSYS

Share
Seoul Viosys to Demonstrate the Unparalleled Value of Its Micro-LED at IFA 2022

Seoul Viosys (“SVC”) (KOSDAQ: 092190), a manufacturer of optical semiconductor devices, will present micro-LED based on the laminated structure – which enables high-resolution display – as well as its micro-LED display products at the IFA (Internationale Funkausstellung Berlin) 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220902005087/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Remarkable color mixing technique developed based on Seoul Viosys’s unique technology (Graphic: Business Wire)

The stacked micro-LED developed by Seoul Viosys has a unique and innovative structure in which three chips representing red, green, and blue (R/G/B) are vertically arrayed instead of the usual horizontal array. Its main difference from conventional micro-LEDs is that its R/G/B LED in the stacked structure emit colors as if they constitute a single pixel through perfect color mixing.

Micro-LED produced by Seoul Viosys can achieve deep black color and clear image thanks to the stacked structure. Also, as colors combining R/G/B are emitted externally from inside a pixel, viewers can enjoy clear pictures without distortions from any direction.

The stacked micro-LED to be presented by Seoul Viosys at the exhibition is based on an innovative future technology that can manufacture 4K display screens between 100 and 200 inches. There will be a space where visitors can experience micro-LED in the company’s booth. It will show two micro-LED displays, including a 54-inch high-resolution 0.625mm pitch (P0.625) display and an 81.5-inch 0.9375mm pitch (P0.9375) display. Visitors will be able to enjoy highly immersive clear pictures wherein each pixel comes alive.

Various products representing key production processes of Seoul Viosys’s micro-LED, which have not been unveiled publicly, will also be on display. By exhibiting epitaxial wafers, cabinets, and other products fabricated using high-level transfer technology of moving micro-LED to a display substrate, the company will offer differentiated prices and quality while demonstrating its distinctive values.

In addition, Seoul Viosys will have an exhibition on its display LED techniques supporting its micro-LED technology, such as the molding technique that controls the moiré phenomenon and highlights the details of the black color, the low reflection technique that helps achieve vivid colors and high contrast ratios in the light, and the customized free form-factor design cabinet display that allows easy installation and replacement of microdisplay and change to various sizes.

As micro-LED has to run stably on extremely low power, it is difficult to achieve technological innovation without LED growth technology. Seoul Viosys already owns quantum efficiency enhancement technology for 1㎛-sized micro-LED through joint research with Nobel Laureate Shuji Nakamura, a professor at UC Santa Barbara, the U.S. The company also operates entire processes from the production of a red-green-blue light-emitting substrate to the manufacturing of devices and modules. Notably, WICOP, Seoul Viosys’s original technology, was applied to its micro-LED. WICOP is a key source technology that is necessary for producing micro-LED. It enables the fabrication of micro-scale chips by using no additional parts such as wires and has high reliability due to process simplification.

“By securing WICOP, a source technology for micro-LED and mini-LED, and quantum efficiency enhancement technology, Seoul Viosys is now ready to address any customer requests,” President Hwang Jeong-hwan of Seoul Viosys said. “Our micro-LED will enable the best image quality that viewers have never experienced before, and offer the top-notch solution in the rapidly changing large display market.”

He continued to say, “Seoul Viosys is introducing its products integrated for the purpose of providing a better solution to our customers, comprising LED, molding, and cabinet technologies, and demonstrating its competence,” once again stressing the company’s management principle of ‘no competition with customers.’

Seoul Viosys will introduce its Real One Pixel product that will be presented at the IFA 2022 on its social channels including YouTube (https://www.youtube.com/watch?v=kMJUzwxDqxk).

About Seoul Viosys

Seoul Viosys is a full-line solution provider for UV LED, VCSEL (Vertical Cavity Surface Emitting Laser), the next-generation light source for 3D sensor and laser, and a single-pixel RGB “Real One Pixel” for displays. Established in 2002 as a subsidiary of Seoul Semiconductor, it captured No. 1 market share in the UV LED industry (LEDinside, 2019). Seoul Viosys has an extensive UV LED portfolio with all wavelengths ranging from 200nm to 1600nm, including ultraviolet rays (UV), visible rays, and infrared rays. The company holds more than 4,000 patents related to UV LED technology. Violeds, its flagship UV LED technology, provides a wide range of industries with optimal solutions for robust sterilization and disinfection (UV-C), skin regeneration (UV-B), water/air purification and effective cultivation for horticulture. In 2018, Seoul Viosys acquired RayCan, a leading optoelectronic specialist, to add advanced VCSEL technology, which supports smartphone facial recognition and autonomous driving, and has started mass production. In January 2020, it introduced a disruptive “Real One Pixel” that has the potential to be a game-changer in the display market. To learn more, visit http://www.seoulviosys.com/en/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220902005087/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye